News

TORONTO – Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease, today announced the completion of a private placement (the “Offering”) of 22,039,472 common shares of the Company (the “Common Shares”) for gross proceeds of CAD$20,981,579.

RAMSEY, N.J., March 18, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 1,225,000 shares of common stock at a public offering price of $8.00 per share, as well as 183,750 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.

ANN ARBOR, MI -- (Marketwired) -- 03/17/15 -- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 (bempedoic acid) compared with placebo in patients with hypercholesterolemia on stable statin therapy.

SAN MATEO, Calif., March 12, 2015— Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced the completion of an $80 million Series B financing. Foresite Capital led the round, with participation from existing investor Longitude Capital and new investors Fidelity Management & Research Company, Aisling Capital, Adage Capital, RA Capital Management and Palo Alto Investors.

MORRISTOWN, NJ – (BUSINESS WIRE) – March 10, 2015 – Pernix Ireland Limited, a wholly owned subsidiary of Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that it has signed a definitive agreement to acquire the Zohydro ER franchise from Zogenix, Inc. (NASDAQ: ZGNX). The acquisition includes three extended release hydrocodone products, including an abuse-deterrent pipeline and all related intellectual property. Pernix has agreed to pay $100 million at closing, plus regulatory and commercial milestones of up to $283.5 million if the Zohydro ER franchise achieves agreed-upon net sales targets of up to $1 billion annually.

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year ended December 31, 2014. 2014 Business Highlights

• Achieved year over year revenue growth of 115%
• Realized 2014 gross margin of 74% versus 55% in 2013
• Completed the RESOLVE study and commenced the RESOLVE II study in December 2014. RESOLVE II is a pivotal Phase III clinical study of the company's RESOLVE steroid releasing implant designed to treat patients with recurrent sinus obstruction in the office setting
• Commenced enrollment in September 2014 of the PROGRESS study to assess the safety and efficacy of the PROPEL® mini steroid releasing sinus implant when placed in the frontal sinus opening
• Completed enrollment in a feasibility study to assess the company's investigational NOVA steroid releasing sinus implant. This implant is designed primarily as a treatment in the physician's office for patients suffering from chronic sinusitis who have not yet had sinus surgery
• Completed an initial public offering in July 2014, raising net proceeds of $55.8 million, after deducting underwriting discounts and commissions and offering expenses

- Full Enrollment of Pivotal SUPPRESS Trial Anticipated in Summer 2015 - - AdVise Enrollment Now Over 100 Patients - DURHAM, N.C., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided an update on its ongoing Phase 3 SUPPRESS trial.

PRINCETON, N.J., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. for a term loan of up to $25.0 million.

RAMSEY, N.J., Feb. 23, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced positive results on the primary and secondary endpoint evaluations from its pivotal Phase III trial for RI-002 in Primary Immune Deficiency Disease (PIDD) in a poster presentation yesterday at the American Academy of Allergy, Asthma and Immunology Annual Meeting (http://annualmeeting.aaaai.org). In December 2014, the company announced that the trial met its primary endpoint with zero serious bacterial infections (SBI).

Proceeds Will Advance Novel Anti-Infectives into Clinical Studies Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the completion of a $42 million private Series B financing. Participants in the financing comprise a syndicate of healthcare-dedicated institutional investors and include both new and existing investors in Cidara.